ABSTRACT-Sepsis accounts for a huge number of deaths in intensive care units all over the world. In 2002, Surviving Sepsis Campaign (SSC) was launched, targeting a mortality reduction of 25% in 5 years. Treatment guidelines were developed, published in 2004 and revised in 2007. An educational program was initiated based on bundles in which 11 of those guidelines were put together to facilitate their assimilation and use. More than 10,000 patients have been enrolled worldwide. However, the SSC and its bundles have been harshly criticized both because of an industry funding and by the presumed fragility of the studies from where they were based. In this review, the main arguments of the SSC critics are discussed and refuted, and the main controversial issues of the resuscitation and management bundles are analyzed, taking into account the new evidence in the literature.
INTRODUCTION
The incidence of sepsis has increased during the past few decades, and mortality rates around the word are unacceptably high (1) . Brazilian rates are even higher, as shown in recent publications described in this supplement (2) .
Surviving Sepsis Campaign (SSC) is a global effort to improve care for patients with severe sepsis and septic shock to decrease such high rates (3) . The campaign, launched by the Society of Critical Care and European Society of Intensive Care Medicine and the International Sepsis Forum in 2002, is now spread throughout the continents; its common objective is to reduce sepsis mortality by 25% in the next 5 years. In this context, guidelines for the management of severe sepsis were developed and published in 2004 (3), which was recently reviewed (4) . A performance improvement program was initiated based on bundles in which 11 of those guidelines were put together to transform the guideline into user-friendly tools to allow clinicians to easily incorporate these new recommendations into bedside care (5) . Bundles are considered important change drivers in clinical practice based on the quality of available published data. Timely intervention is emphasized, and the bundles were named for 6 or 24 h, which means that the assigned interventions are to be performed within these time windows after the diagnosis of severe sepsis.
However, both the SSC and the bundles have been harshly criticized recently (6) . This review aims to discuss the postulated reasons of the recent campaign against SSC and to discuss, in an evidence-based approach, the most controversial intervention for each bundle.
THE SSC AS A TARGET
In recent months, the SSC itself has been strongly criticized by a number of authors (6, 7) . Their criticisms include the fact that sponsors of the SSC were too closely aligned with the process, and that this closeness can make the integrity of the guidelines questionable. Moreover, they argue that the guideline implementation process has become part of a marketing strategy for one of the sponsors, the Eli Lilly Company (6, 7) .
Guidelines are instruments to improve clinical practice, but rarely do they achieve such objective. The SSC performance improvement program was developed to assess this problem. For the first time, a disease responsible for such a large number of deaths worldwide is the target of a campaign to improve mortality rates. Never before has a disease entity as severe as sepsis/septic shock with such a high rate of death been targeted for a systematic process and outcome improvement worldwide. In all continents, networks are being formed to fight against the disease. These days, the leaders of these networks are being accused of generating all this movement to sell a drug or equipment for continuous measurement of central venous oxygen saturation (ScvO 2 ) (7).
The SSC seems to welcome a constructive form of criticism such as those who argue against bundle components or also interventions that were not included in the guidelines (8) . Many of the critics of the bundles seem to have been taking into account the generation of the revised guidelines as will be discussed in the succeeding sentences (4). Regarding topics not addressed, selective decontamination of the gastrointestinal tract deserved a comment on the revised guidelines (4), but nutritional strategies, mostly those related to immunonutrition, are still lacking. However, the dynamic nature of the recommendations will allow them to change and follow the evidence available, whereas the spirit of the bundles will be preserved.
The relationship between industry and the scientific community cannot be viewed as necessarily unethical. In regard to the SSC, it is easy to conclude that there is a common point of interest. The industry's first objective is to make a profit. The first objective of the campaign is to save lives. These points are not conflicting per se. For the industry, the spreading of the SSC concepts increases the absolute number of patients who will be considered to use a drug or a device. For the scientific community, the industry funding allows the spread of SSC concepts and, if the correct population actually receives a specific drug or device, there is nothing unethical regarding it. Therefore, the problem is not the funding itself but how this funding has been used. The question is whether industry sponsorship of the SSC can actually lead to the development of a specific content in the guidelines. This seems quite improbable because the number and excellence of the societies and experts involved preclude any attempt to override ethics.
The use of sponsors to support the process was not considered ideal; however, other streams of funding were not readily available, and it was thought that careful handling of the situation would enable a clear and transparent method to support the process (8) . In the development of the 2004 guidelines, the SSC stated in numerous publications that industry support was limited to funds for logistic planning (8, 9) . No industry representative participated in the conference or reviewed the guidelines. To prevent unwarranted criticism, the Society of Critical Care and European Society of Intensive Care Medicine decided to fund the effort without industry sponsorship when the SSC guideline revision process was begun in 2006 (4, 8, 9) . The rules for evidence-based classification were previously well recognized as adequate by the medical community. In 2004, activated protein C (APC) received a B recommendation based on the fact that one, and only one, randomized control trial demonstrated its efficacy (10) . On the current revision, under a new grading system, it was graded as a weak recommendation (4) . It is clearly stated in the guidelines that either intermittent or continuous measurements of oxygen saturation are judged to be acceptable (3, 4) . Regarding the performance improvement program, hospitals are required to develop and follow their own policy on the appropriate administration of drotrecogin ! activated (DAA), which in many countries means that they will not administer it at all. There is no mention regarding a preferable use of continuous ScvO 2 measurement (5).
Many national networks also assume that industry funding is essential because government funding is not yet available. Transparency regarding disclosure of potential conflicts of interest is not a definitive solution to the possibility of undue influence, but this disclosure is an important step toward a broader solution. However, it will be much easier to deal with the skeptics through the creation of public funding mechanisms, and efforts are being made in this direction. In the meantime, the hundreds involved in the SSC will press forward to reduce mortality attributable to severe sepsis with the resources available. So far, these unselfish health care professionals in 15 countries have included in the educational program up to 10,000 patients (9) in an unprecedented effort of a worldwide critical care community against sepsis.
THE SSC BUNDLES AS TARGETS

Early goal-directed therapy
The early goal-directed therapy (EGDT) is one of the milestones of the SSC resuscitation bundle (11) . The resuscitation bundle represents only current accepted good practice. It just says that doctors should give enough fluids to patients with hypoperfusion until a target is reached (central venous pressure [CVP] , 8Y12 mmHg), they should give vasopressors in the presence of hypotension to a preset point (MAP, 65 mmHg), and they should optimize oxygen delivery to targets as urinary output (0.5 mL kg j1 h j1 ) and ScvO 2 (70%). Moreover, it is centered on early detection and treatment of sepsis. Therefore, it is reasonable to ask why such controversy was created regarding those standards of care.
One of the arguments against it is that EGDT is based only on a single-center study, and that the benefits of such protocol cannot be considered high-quality evidence. However, other studies have already reproduced the experience in the emergency department (ED), showing both the feasibility and even a mortality reduction when compared with historical controls (12) . A multicenter, randomized, controlled trial of EGDT in ED is being conducted by the National Institutes of Health, and in a few years, we should be able to see the results.
A further point in the problem for a large-scale protocol implementation in ED worldwide is the argument, thought to be impossible by some critics and unnecessary by others, that most ED patients are not candidates for EGDT (13) . Despite the evidence in favor of EGDT, the implementation of this practice is incomplete. A recent emergency medicine survey involving physicians from 30 academic tertiary care hospitals found that only 7% reported using EGDT (14) . This is undoubtedly a challenging problem, and a recently survey identified the lack of available nursing staff to perform the procedure, the inability to monitor central venous pressure in the ED, and challenges in identifying septic patients as the most frequent barriers. Other barriers were physical space in the ED, lactate and ScVO 2 monitoring, and transfer of care between ED and intensive care unit (ICU) teams. However, lack of agreement with the EGDT was mentioned as a barrier by a minority of the physicians (15) . Although it is true that the protocol is overtasking, we should have in mind that there is no short cut to success, and none of these barriers are unbridgeable, all tending toward an easier implementation as the team gets used to the protocol.
The filling pressures used in EGDT were also a matter of debate. We know now that the use of static measures to assess the volemic status of the patients such as CVP or pulmonary artery wedge pressure are questionable in critically ill patients. A rise in preload will only lead to an increase in cardiac output if the ventricles are at the ascendant portion of the Frank-Starling curve. Therefore, in fluid responsiveness determination, the use of dynamic parameters seems to work better (16) . The use of pressure pulse variation has been validated in septic patients as a way to assess fluid responsiveness (16) . However, the method has an important limitation because the patient needs to be under mechanical ventilation with tidal volume of 8 mL kg j1 body weight, well sedated and without arrhythmias. For patients in spontaneous ventilation, predicting volume responsiveness remains a challenging problem.
However, besides its limitations, most of the patients with CVP of 8 to 12 mmHg will not respond to volume. Because the campaign should be directed to achieve most of the patients, these limits seem quite reasonable. Moreover, the choice of CVP was due to its wide availability. Volume replacement greater than those limits should be considered in clinical situations such as decreased ventricular compliance, high intra-abdominal pressure, diastolic dysfunction, preexisting pulmonary hypertension, or during mechanical ventilation. In those patients, high levels of CVP must be targeted, as already suggested in the SSC guidelines (12Y15 mmHg) (4). It is also suggested that CVP should be assessed as a dynamic variable before and after a volume challenge, and, if possible, other variables should also be analyzed such as cardiac output, arterial pressure, heart rate, and ScvO 2 (3, 4) . This latter parameter, ScvO 2 , is also claimed to be controversial. Intensivists may argue that ScvO 2 does not accurately reflect the mixed venous oxygen saturations (SvO 2 ), and that pulmonary artery catheterization is preferable if an accurate value is to be obtained. It is true that the differences and limits of agreement between the two variables can be considered clinically significant (17) . It is also true that SvO 2 is a more robust measure of oxygen delivery because it takes into account not only the blood that comes from the inferior vena cava but also the deoxygenated blood derived from coronary sinus because myocardium has a high oxygen extraction fraction. It is estimated that SvO 2 is 5% lower than ScvO 2 on average (17) , but the studies have compared SvO 2 and ScvO 2 in the normal to high range, which is found in the latter stages of sepsis and in ICU patients. However, it should be emphasized that the only parameter that has been validated as a therapeutic target in the early phases of sepsis was a ScvO 2 of 70% (11) . Thus, the questionable parameter, if at all, would be the SvO 2 or its target value, not ScvO 2 . Actually, this seems to be a nonsense discussion because both are measuring the same physiological phenomena and are potentially interchangeable. Previous studies failed to show SvO 2 as an adequate target for resuscitation (18) , but this finding can be related to the fact that time for intervention was not considered as a criterion, unlike the study of Rivers et al. This timely relationship was already suggested by a metaanalysis (18) . As already mentioned, Rivers et al. used a central line capable of providing continuous ScvO 2 monitoring. However, an adequate level of monitoring can be achieved by using intermittent sampling from the central line and feeding samples through a blood gas analyzer. It is just more workload. The SSC recognizes that either SvO2 or ScvO 2 can be used with different targets (65% and 70%, respectively), and that either way, intermittent or continuous sampling is adequate (3, 4) .
Another point is what should be done to optimize ScvO 2 , rather than giving fluids. Rivers et al. oriented that a hematocrit of 30% should be first obtained and only after that should dobutamine be used. In the guidelines, both are considered adequate, with no orientation regarding which one should be attempted first (3, 4) . The reason for that position is clearly the fact that giving red blood cells is not a harmless decision, and doctors should feel free to decide until new evidence is available.
The ideal hemoglobin (Hb) level has not yet been determined in patients with severe sepsis or septic shock. A randomized study in critically ill patients has already shown that an Hb of 7.0 g dL j1 is safe, but the subgroup of septic patients was not analyzed (19) . It is not clear whether levels greater than this value are helpful in increasing tissue oxygen consumption (20) . Moreover, blood cell transfusion has been associated with an increased risk for nosocomial infection as a consequence of transfusion-related immunosuppression (21) . In the septic population, the potential harms also include a decrease in blood viscosity associated with the transfusion, mostly of old stored blood, because red cells have a decreased deformability and an alteration of 2-3DPG that hampers oxygen delivery progressively during storage (21) . These concerns gave rise to the idea that it would be better to improve cardiac output instead of the Hb capacity of oxygen transport. Myocardium depression is a well-established feature in early septic shock with many possible physiopathological mechanisms (22) . On the other hand, dobutamine use was never submitted to a clinical trial in sepsis, and its potential harmful effects are not known. Therefore, until more evidence is available, SSC states that ScvO 2 , or SvO 2 , should be optimized with the adequate use of fluids and either red blood cells or dobutamine (3, 4) .
Corticosteroids
The use of corticosteroids in sepsis treatment has a long and controversial story that has already passed from high doses to control inflammation and, more recently, low doses to treat adrenal dysfunction. This long and winding story is compatible with the multiple and intricate effects of glucocorticoids in our organism that provided a background for many clinical studies focused on the usefulness of corticosteroids in septic shock management (23) . Corticoid studies are markedly controversial not only regarding doses and time of administration but also regarding the diagnosis criteria for adrenal dysfunction. Previous studies using high doses to modulate inflammation have shown an increased death risk (24) . However, recent low-dose studies suggested that those patients can benefit from the drug (24) .
The most important study published is still the work of Annane et al. (25) in 2001, in which the use of 200 mg of hydrocortisone was associated with a reduction of approximately 10% in the mortality rate in a group of 300 septic shock patients. This reduction was due to the effects in a subgroup of patients that failed to respond adequately to an adrenocorticotropic hormone (ACTH) test.
However, Corticosteroid Therapy of Septic Shock, a study that has not been published yet but already presented in scientific meetings, was not able to confirm these findings (26) . The use of the same dose of hydrocortisone resulted in no mortality reduction in nonresponders, responders, or in the overall population, although it did reduce the time to shock reversal. Albeit we need to see the published form of the study, it is possible to hypothesize many explanations for these discrepant results. First, patients in the trial of Annane et al. were much sicker (placebo mortality, 60.0%) because their inclusion criteria required not only to be in septic shock but also to be hypotensive for 1 h despite the use of vasopressors, characterizing a refractory or rapidly progressive hemodynamic derangement. Moreover, the patients had to be in mechanical ventilation and with at least another organ dysfunction (renal, respiratory, or lactate acidosis). Second, there was a higher number of patients with adrenal failure in the first study, probably as a consequence of a greater severity of the disease. This might have increased the need for corticoid reposition and, hence, the response to this therapy. Third, in the first study, the use of hydrocortisone was accompanied by the use of fludrocortisone, a mineralocorticoid with possible vasoactive effects.
These controversial results raised the concern regarding the potentially harmful effects of corticosteroids in a septic population. Regardless of the fact that no increase in infectious complication or in the incidence of polyneuropathy could be found in both studies, this is not an unquestionable finding because neither study was sized to detect those differences. In addition, the necessity to perform an ACTH test is under question because there are many pitfalls regarding timing, accuracy, and even diagnosis criteria of this test.
In this scenario, the SSC changed its 2004 recommendation in the new guidelines. Now, it is suggested that corticosteroids in low doses should be used only in poorly responsive septic shock cases. The use of high doses and the ACTH test is not recommended (4).
Glycemic control
Hyperglycemia and peripheral resistance to insulin are common in ICU patients, whether diabetic or not. Traditionally, ICU physicians would not interfere until glycemia reached 180 to 200 mg dL j1 because those levels were thought to be a physiological response to stress and necessary to ensure glucose to cells in the presence of insulin resistance. However, during the past few years, a large amount of evidence has shown hyperglycemia to be associated with adverse effects in many critical scenarios such as trauma, acute myocardium infarction, and brain attack.
The first study to ever show a mortality reduction with tight glycemic control (80Y110 mg dL j1 ) was the surgical patient trial in 2001 of Van den Berghe et al. (27) . They were also able to show a reduction in the incidence of dialysis, bacteremia, polyneuropathy, and number of red blood cell transfusion, as well as ICU and hospital length of stay. However, in 2006, the same group published another article, this time on a clinical patient population (28) . In this trial, no mortality reduction was found (37.3% intensive vs. 40.0% control) except in the subgroup of patients that stayed in the ICU for more than 3 days (43% vs. 52.5%; P = 0.009). One of the inclusion criteria was a predicted length of stay greater than 3 days, but the authors could not correctly predict it, because nobody can, so a high number of patients (433/1,200 patients) stayed in the ICU for less than 3 days. In this subgroup, the tight glucose control was associated with a higher incidence of death (28) . When 65 patients, in which a do-not-resuscitate (DNR) order was given in the first 3 days, were excluded from analysis, this difference in mortality disappeared. Such patients' exclusion sounds strange because DNR order at admission was an exclusion criterion. It suggests that the DNR orders in the first 3 days were more related to an unfavorable evolution than to the severity of baseline characteristics. It is not possible to exclude that those patients had a worse outcome because of the tight glycemic control.
One of the possible reasons is the presence of hypoglycemia because the authors did not state if the incidence of hypoglycemia in this subgroup (G3 days and tight control) was higher. A major concern regarding the clinical population is the higher incidence of hypoglycemia compared with the surgical population (18% vs. 6.2%). Hypoglycemia seems to be associated with a worse prognosis. Although the authors did not analyze this question, the 73.3% hospital mortality rate in hypoglycemic conventional treatment patients and the 61.9% hospital mortality rate in the hypoglycemic-intensive subgroup (P = 0.4) are worrisome because they are much higher than the global mortality rates, suggesting that hypoglycemia is really associated with death. We cannot be sure because it is possible that hypoglycemia is just a marker of disease severity and not a risk factor per se. However, in their clinical study, Van den Berghe et al. stated that hypoglycemia was related to mortality in a multivariate analysis, although the data were not shown.
The difference in hypoglycemia rates between the clinical and surgical study might be explained by the higher incidence of renal and hepatic dysfunction in the former. We can hypothesize that the potential benefits from tight control could have been overcome by the deleterious effects of hypoglycemia or normoglycemia in the first days in the ICU when the inflammatory response is maximum, and peripheral insulin resistance can hamper the appropriate use of glucose if serum levels are Bnormal[.
Another problem with the trials of Van den Berghe et al. is that both are single-center studies. The not-yet-published European Glucontrol trial, a multicenter, randomized study designed to test the same hypothesis, was presented in a recent scientific meeting, with results that seem to be very disappointing because no mortality reduction can be found (29) . However, we must wait for the entire data to be published. The same applies to the results of the Volume Substitution and Insulin Therapy in Severe Sepsis trial, designed to evaluate not only the effects of hyperglycemia but also two types of fluid resuscitation in septic patients. This latter study was the only one to specifically analyze the septic population, but the results have not been published yet (30) . However, in a congress presentation, it seems that no mortality impact can be found.
When Van j1 was more effective than at 110 to 150 mg dL j1 but also carried the highest hypoglycemia risk (31) . However, because risk of hypoglycemia in both conventional and intensive insulin groups coincided with a higher risk of death, it cannot be completely excluded that hypoglycemia counteracted some of the survival benefits of tight control.
Therefore, although tight glucose control is under great controversy, some control is not. The conventional group approach in the protocol of Van den Berghe et al. recommended that insulin should be started as glycemia reached 215 mg dL j1 , with a target level of 180 to 200 mg dL j1 . This means that there is a wide gap between the two groups, and it was exactly this gap that the SSC took into consideration in creating the guideline. The SSC has been criticized because of the recommendation for glucose control. However, this is unfair because in the 2004 guidelines and also in the new 2007 version, the target level suggested by the SSC was 150 mg dL j1 , with the strict recommendation to avoid hypoglycemia (3, 4) .
Protein C, one of our natural anticoagulants, is produced by the liver and activated in the circulation, where it acts by cleavage and inhibition of factors Va and VIIIA. Activated protein C exerts an indirect anti-inflammatory action by inhibition of thrombin generation, and it can modulate inflammation also through direct effects. The APCYprotein S pathway is seriously compromised in sepsis, both due to a decrease in protein C levels, as a result of a reduced liver production, and a high consumption due to the exacerbated coagulation, as well as the reduction in activation mechanisms. The reduced APC levels compromise not only its anticoagulation actions but also its anti-inflammatory and profibrinolytic functions, and they have been associated with a higher mortality rate.
In 2001, Protein C Worldwide Evaluation in Severe Sepsis (PROWESS), the first double-blind, placebo-controlled trial with DAA, the recombinant form of APC, showed a significant reduction in overall 28-day mortality (6.4%), with a relative reduction of approximately 20% (10) . This was the first study to have ever shown mortality reduction in sepsis and to be welcomed by the scientific community. Approval from the US Food and Drug Administration followed the presentation of these results.
However, during the past few months, DAA has been increasingly criticized by this same community based on old and new drawbacks. Some criticisms have been made regarding changes to the protocol in the exclusion criteria, product manufacture, and the placebo used. Before the amendment, no reduction in mortality was found, only after those protocol changes. However, we can easily justify this finding by the learning curve of the investigator sites because the beginning of the effect can be seen before the amendment approval. One of the major PROWESS findings was that DAA has a better impact on mortality reduction in severely ill patients, markedly those with an Acute Physiology and Chronic Health Evaluation (APACHE) II score greater than 25. Patients with two or more organ dysfunctions also had a higher reduction. After PROWESS, we had Extended Evaluation of Recombinant Human Activated Protein C (ENHANCE), an open-label study that confirmed the previous findings, including improved survival mainly among the more severely ill patients (32) . ENHANCE also showed that the mortality reduction effect was greater in the patients that received the drug in the first 24 h of installation of organ dysfunction.
The first years of drug use were marked by an effervescent effect where, certainly, a drug was given inadequately for some patients. The Administration of Drotrecogin ! (Activated) in Early-Stage Severe Sepsis (ADDRESS) study, aimed at investigating the effects of DAA in less severely ill patients, has shown that they did not benefit from the drug (33) . This was a very important step in DAA history because it helped a great deal to clarify the real target population for DAA use. It is now clear that patients with only one dysfunction, mostly if they are surgical ones, and patients with APACHE II score less than 25 should not be considered DAA candidates. However, in this study, a small number of patients with APACHE II score greater than 25 did not benefit from the drug either. This stimulated the drug critics even more because it backs their arguments against PROWESS and ENHANCE data showing a better benefit for such patients. Nonetheless, it should not be forgotten that the study has as an inclusion criterion the investigator's feeling of low risk of death. In addition to being quite subjective, it seems to have worked because the mortality rates, when only the placebo groups are analyzed, were lower in ADDRESS APACHE II greater than 25 group than in PROWESS same group (24.6% vs. 43.6%). It is also interesting to notice that even patients in the placebo group with multiple organ dysfunctions, a wellknown mark of severity, presented with low mortality rates (21.8%), suggesting that the clinical judgment was superior to these risk factors in mortality prediction. It should be emphasized that APACHE II can be a reliable score in a group of patients, but its use as an individual score to indicate a specific therapy is an unprecedented medical recommendation, at most with data collection beyond the first 24 h of ICU admission. Never has this score been used before in this way, and never has it been validated as a prescribing index. Moreover, APACHE II can change over time, and very severely ill patients can have their score changed by the use of large amounts of vasoactive drugs or positive end expiratory pressure.
One of the major drawbacks to DAA use, besides its high financial costs, is the cost in adverse effects, namely, bleeding. In real life, the incidence of severe bleeding is higher than the one reported in the randomized protocols, probably because these protocols have many exclusion criteria (34, 35) . These exclusions are necessary to provide a homogeneous population that will not die of a baseline disease but because of sepsis. The discrepancy between study population and reallife patients is well known. Severely ill patients and those with relative contraindications regarding bleeding are usually excluded from trials, but they constitute an available population, even a preferred one, for commercial use. However, this hampers the extrapolation of the results to the usual ICU population, usually with higher mortality and bleeding rates. In the presence of a higher incidence of bleeding, the mortality reduction effect is more difficult to demonstrate because of an altered cost-benefit ratio. This unbalance is clearly stated in observational studies.
In a recently published Canadian study, the incidence of severe bleeding (10%) was higher than that of Lilly's trials (PROWESS, 5.3%; ENHANCE, 6.5%; and ADDRESS, 3.9%) and the overall mortality rate (45.2%). A relative contraindication to DAA was predictive of a serious adverse bleeding event. However, the use of DAA in the first 24 h of dysfunction was still associated with mortality reduction (OR, 0.51 95% CI, 0.28Y0.92) (34) .
Another common problem is the out-of-label commercial use. In a recent Italian observational study (35) , the number of patients that use the drug outside the 48-h window (21.3%; within the group, these data were collected) or with none or only one organ dysfunction (5.7%) was high. Infected patients without sepsis that received the drug accounted for 7.2% of the cases. Almost 5% use the drug with platelet levels under 30,000 mm j3 . Out-of-label use reached 27.6% in the group of patients included after 2005. It is not surprising that the incidence of bleeding was higher (10.9% during the infusion), and that the mortality benefit was more difficult to demonstrate. Even in this scenario, DAA was associated with a significant mortality reduction of 8.6% (P = 0.004), although in the multivariate analysis, it was not. Actually, its use was associated with higher mortality after scheduled surgery (35) . This is a typical example of how a misuse can make the risks outweigh the potential benefits. Therefore, it is important to assume that if the clinical trial risk-benefit ratio is to be achieved in real life, we must define clearly the patients who are really at a high risk of death.
This misunderstanding of the right population is nowadays a central issue. One of the major problems with all DAA studies is that they were conducted before the SSC era. Our understanding of sepsis pathophysiology and standard treatment is now much improved, and many of the basic concepts were not known by that time. Although all studies had an inclusion criterion, a limitation of 48 h since installation of organ dysfunction, any of these protocols took into account the type of care received by the patients in the first few hours of treatment. None of them assessed SSC bundle adherence. Some aspects should be considered. First, we cannot be sure regarding the real effects of DAA because the groups not necessarily received the same therapies, and that the randomization process was not tested regarding these parameters to assure equality between the groups. Second, many experts now think that DAA should be used only in patients receiving the best standard of care. It means that patients who persist with organ dysfunction or who develop a new dysfunction after adequate hemodynamic resuscitation are actually the adequate candidates to DAA. Therefore, the outcome behavior of the dysfunction seems to be much more important than their number or severity. A patient that is admitted to the hospital comatose, in a prearrest hemodynamic and respiratory state, with low platelet levels and lactic acidosis, requiring high doses of vasopressors and who, after adequate volume replacement in the first few hours, is awake, withdrawing vasopressors, and with an adequate lactate clearance would not be an adequate candidate to DAA therapy despite the presence of five initial organ dysfunctions. This concept of high risk of death is the best one we have so far to describe the target population for DAA, albeit we are not able to define it. This is such an important issue that in the current study conducted by Eli Lilly, aimed at assessing DAA 96-h infusion efficacy in a group of septic shock patients, compliance with a resuscitation policy is an inclusion criterion, and only patients with persistent signs of hypoperfusion after the resuscitation phase will be included and randomized to receive the drug or placebo.
Therefore, the correct identification of the eligible patient to DAA seems to be more difficult in real life. The target population for the drug is not settled, and, definitely, what a Bhigh risk of death[ is has not been made clear yet. Acute Physiology and Chronic Health Evaluation II, number of organ dysfunctions, and even the presence of shock alone do not seem to be good markers of severity at least regarding the DAA indication. All theses issues should have been taken into account in the SSC board decision to classify DAA as a weak recommendation (4) . Until more data are available better defining the ideal patient for DAA use, it is suggested that DAA should be used in those with a high risk of death and without any contraindication.
CONCLUSIONS
Surviving Sepsis Campaign is an international network aimed at reducing sepsis mortality. The two main strategies are the generation of guidelines and the implementation of the performance improvement program based on bundles. The critics regarding funding are worried because they can reduce the impact of the campaign. Efforts are being made to have maximum transparency regarding disclosure of potential conflicts of interest and also in the creation of public funding mechanisms. Critics regarding the bundles are pertinent, but the dynamic nature of the recommendations will allow them to change as the recently published 2008 revision already have.
The main concerns in the bundles are the widespread use of EGDT, corticosteroids, tight glycemic control, and DAA. The resuscitation bundle represents only a slight modification of current good practice and is well suited for a campaign regardless of some controversial issues such as feasibility, appropriate filling pressures, and usefulness of SvcO 2 . Corticosteroids seem to be useful only in refractory septic shock patients, and its safety is not completely assured. Whereas tight glucose control is under great controversy, some glycemic control is not. Therefore, it seems more appropriate to guide therapy to a less tight target of 150 mg dL j1 , with the strict recommendation to avoid hypoglycemia. Drotrecogin ! activated should be used only in patients with high risk of death and without contraindications. However, the identification of such patients is not easy in daily practice, and it is hoped that the new trial will show us the answer.
